CTOs on the Move

Acrivon Therapeutics

www.acrivon.com

 
Acrivon Therapeutics is a precision oncology therapeutics company uniquely enabled by a differentiated proteomics-based patient selection platform.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Acrivon Therapeutics raised $15.5M on 02/12/2021

Similar Companies

Kratos Analytical

Kratos Analytical is a Spring Valley, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PrecisionMed

PrecisionMed Inc. is a Solana Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Brijen Biotech

Brijen Biotech is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Muse bio

Muse bio is transforming genome engineering by enabling, for the first time, high throughput massively-multiplexed CRISPR editing of proteins, pathways, and genomes. Through our powerful bioinformatics and novel molecular approach, ForgeCraft generates low-cost libraries of thousands of designer protein, pathway, or genome variants each with specifically defined, trackable mutations. This allows the impact of specific changes to be determined through rapid selection and high throughput screening allowing research timelines and costs to be reduced.

DBV Technologies

DBV Technologies (DBV) is a clinical-stage biopharmaceutical company focused on discovering safe and effective treatments for patients with food allergies and other unmet medical needs. DBV has developed a proprietary technology platform called Viaskin®, which is based on epicutaneous immunotherapy, or EPIT®, DBV`s method of delivering biologically active compounds to the immune system. This novel mechanism of action accesses the immune system through intact skin without allowing passage of the antigen into the bloodstream. The company is also exploring Viaskin® in other areas of unmet need including vaccines, inflammatory conditions and autoimmune diseases. DBV was founded in 2002 by Dr. Pierre-Henri Benhamou, Chairman and CEO, Dr. Christophe Dupont, Chairman of DBV`s Scientific Advisory Board, and Mr. Bertrand Dupont, Chief Technology Officer.